Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Zealand Pharma A/S

ZLDPFPNK
Healthcare
Biotechnology
$56.62
$0.00(0.00%)
U.S. Market opens in 9h 43m

Zealand Pharma A/S Fundamental Analysis

Zealand Pharma A/S (ZLDPF) shows strong financial fundamentals with a PE ratio of 3.95, profit margin of 70.06%, and ROE of 47.93%. The company generates $9.2B in annual revenue with strong year-over-year growth of 145.99%.

Key Strengths

ROE47.93%
Operating Margin75.54%
Cash Position374.04%
PEG Ratio-0.86
Current Ratio23.57

Areas of Concern

No major concerns flagged.
We analyze ZLDPF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 99.7/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.

Fundamental Health Score

A
99.7/100

We analyze ZLDPF's fundamental strength across five key dimensions:

Efficiency Score

Excellent

ZLDPF demonstrates superior asset utilization.

ROA > 10%
39.31%

Valuation Score

Excellent

ZLDPF trades at attractive valuation levels.

PE < 25
3.95
PEG Ratio < 2
-0.86

Growth Score

Moderate

ZLDPF shows steady but slowing expansion.

Revenue Growth > 5%
145.99%
EPS Growth > 10%
6.64%

Financial Health Score

Excellent

ZLDPF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.03
Current Ratio > 1
23.57

Profitability Score

Excellent

ZLDPF achieves industry-leading margins.

ROE > 15%
47.93%
Net Margin ≥ 15%
70.06%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is ZLDPF Expensive or Cheap?

P/E Ratio

ZLDPF trades at 3.95 times earnings. This suggests potential undervaluation.

3.95

PEG Ratio

When adjusting for growth, ZLDPF's PEG of -0.86 indicates potential undervaluation.

-0.86

Price to Book

The market values Zealand Pharma A/S at 1.72 times its book value. This may indicate undervaluation.

1.72

EV/EBITDA

Enterprise value stands at 4.25 times EBITDA. This is generally considered low.

4.25

How Well Does ZLDPF Make Money?

Net Profit Margin

For every $100 in sales, Zealand Pharma A/S keeps $70.06 as profit after all expenses.

70.06%

Operating Margin

Core operations generate 75.54 in profit for every $100 in revenue, before interest and taxes.

75.54%

ROE

Management delivers $47.93 in profit for every $100 of shareholder equity.

47.93%

ROA

Zealand Pharma A/S generates $39.31 in profit for every $100 in assets, demonstrating efficient asset deployment.

39.31%

Following the Money - Real Cash Generation

Operating Cash Flow

Zealand Pharma A/S generates strong operating cash flow of $6.89B, reflecting robust business health.

$6.89B

Free Cash Flow

Zealand Pharma A/S generates strong free cash flow of $6.86B, providing ample flexibility for dividends, buybacks, or growth.

$6.86B

FCF Per Share

Each share generates $97.38 in free cash annually.

$97.38

FCF Yield

ZLDPF converts 27.03% of its market value into free cash.

27.03%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

3.95

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.86

vs 25 benchmark

P/B Ratio

Price to book value ratio

1.72

vs 25 benchmark

P/S Ratio

Price to sales ratio

2.76

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.03

vs 25 benchmark

Current Ratio

Current assets to current liabilities

23.57

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.48

vs 25 benchmark

ROA

Return on assets percentage

0.39

vs 25 benchmark

ROCE

Return on capital employed

0.44

vs 25 benchmark

How ZLDPF Stacks Against Its Sector Peers

MetricZLDPF ValueSector AveragePerformance
P/E Ratio3.9529.45 Better (Cheaper)
ROE47.93%779.00% Weak
Net Margin70.06%-24936.00% (disorted) Strong
Debt/Equity0.030.26 Strong (Low Leverage)
Current Ratio23.574.65 Strong Liquidity
ROA39.31%-19344.00% (disorted) Strong

ZLDPF outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Zealand Pharma A/S's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

1319.46%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

514.90%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

616.17%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ